Treats Gaucher disease type 1 (GD1). Sold as Cerdelga. Every FDA application for this active ingredient: 1 branded and 6 generic.
As of Nov 22, 2026, FDA lists 7 applications for Eliglustat tartrate (sold as Cerdelga), first approved Aug 19, 2014, with 1 new use approved and 0 published complete response letters.
| Aug 19, 2014 | CerdelgaNDA 205494 · New molecular entity | Genzyme | 3 | Marketed |
| Sep 8, 2021 | Eliglustat TartrateANDA 212463 | Aizant | 0 | Marketed |
| Dec 27, 2021 | Eliglustat TartrateANDA 212474 | Teva Pharmaceuticals USA | 0 | Discontinued |
| Aug 17, 2022 | Eliglustat TartrateANDA 212449 | Dr. Reddy's Laboratories | 0 | Discontinued |
| May 2, 2023 | Eliglustat TartrateANDA 212420 | Upsher-Smith Laboratories | 0 | Marketed |
| Jul 10, 2024 | Eliglustat TartrateANDA 212425 | Apotex | 0 | Discontinued |
| Dec 10, 2024 | Eliglustat TartrateANDA 212369 | Cipla | 0 | Discontinued |
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Cerdelga | Part D | $53.2M | +26% | 168 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA